Last reviewed · How we verify
PK of Lidocaine/Tetracaine and PD Derived From a New Topical Formulation for Treatment of Neuropathic Pain. (PK/PDLido)
Post-herpetic neuralgia (PHN) is the most frequent complications related to herpes zoster, and can persist for months or even years, and require extensive treatment. For this purpose, pharmacological therapies based on tricyclic antidepressants (amitriptyline), central nervous system depressants (pregabalin) and also opioids, have been stablished. However, all the drugs mentioned can cause serious systemic adverse effects that worsen the patient's quality of life. To avoid these complications, topical therapies based on Capsaicin or Lidocaine 5% patches have been developed. However, these treatments have shown dissimilar results in controlling PHN, so a mixed formulation of lidocaine/tetracaine could show better results. For these reasons, the main objective of our work is to evaluate the plasma levels of lidocaine derived from the application of a topical formulation of lidocaine derived from the application of a topical formulation of lidocaine 23%/tetracaine 7% in patients with neuropathic pain.
Details
| Lead sponsor | Pontificia Universidad Catolica de Chile |
|---|---|
| Status | COMPLETED |
| Enrolment | 20 |
| Start date | Fri Mar 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Jul 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Neuralgia
- Neuropathic Pain
- Local Anesthetic Complication
- Lidocaine Adverse Reaction
Interventions
- Lidocaine topical
Countries
Chile